Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

First International Summit on Interventional Pharmacoeconomics

Opening Session Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Amit Sanyal, MD: A Clinician’s Perspective

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Jun

Today In Oncology

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Related Videos

Opening Session Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Amit Sanyal, MD: A Clinician’s Perspective

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

AML All-Oral Regimen Safe and Eases Treatment Administration Burden

Study Identifies Serious Infection Risks Linked to Antibody-Drug Conjugates

Overall Survival With EBRT in Hepatocellular Carcinoma

SCLC With Brain-Only Progression Original or Substitute Systemic Therapy With or Without Brain Radiotherapy

Five-Year Survival Analysis: Neoadjuvant Trastuzumab-Pertuzumab Plus Endocrine Therapy or Chemotherapy in HR-Positive/HER2-Positive Breast Cancer